… business prospects of BioMarin Pharmaceutical Inc., including expectations … hypochondroplasia expected in the first half of next year … conditions portfolio in the first half of next year, … revenue outlook for 2025. We have delivered expanding profitability …

… pharmaceutical products. Net profit for 2024 amounted to 521.005 million rubles, revenue … development and wholesale of pharmaceutical products. The Group… operating in the pharmaceutical market of the … its net profit under IFRS for the first half of …

… 11.6% 50.7% Ascentage Pharma Group International (SEHK:6855 … reported substantial revenue and net income increases for H1 2025. … promising growth prospects with revenue expected to grow … Operations: The company generates revenue through its activities in …

… recorded a profit of 96 million francs for the first half of the … ,5 billion for 89Bio. •SERB Pharma purchased Y-mAbs Therapeutics for …

… with Tau proteoforms in the first half of 2026. “In Q3 … Tau proteoforms in the first half of 2026 and expanding … with respect to any revenue timing or projections; expectations … proteome or proteoform access, pharmaceutical development and drug discovery, …

… double-digit growth and steady profitability. This performance was driven … APAC and EMEA from Janssen Pharmaceutica. In India, we … North American generic business generated revenues of $373 million for … a small extent in the first half numbers? Or should we …

… equipment posted third quarter revenue that missed estimates. NXP … results from heavyweight Swiss drugmaker Novartis and French banking … banking firm raised its profitability outlook for 2025 while … of expectations in the first half Amundi shares rise as …

… performance. Overall, the company generated revenue of $699 million in the … as we had in the first half of the year. I think … it is more on the pharma pharma biotech side and not obviously … lab, every researcher in pharma big pharma biotech has signals at their …

… is not expected until the first half of 2026. Meanwhile, Apple… care services (Optum Health), pharmacy services (Optum Rx), and … 18% in the first half of 2025 as its profit margin contracted. … to concerns about falling profits and the ongoing investigations. …

… for illegally selling Schedule H1 drugs (Spasmo-Proxyvon … strip, thereby earning illegal profit. Several local consumers, … the alarming spread of pharmaceutical drug abuse. Further investigation … was illegally selling Schedule H1 drugs (Spasmo-Proxyvon Plus …